Physician profile
Kathryn Ham
NPI 1588140107
$1,945.63
in general payments reported to CMS, 2019-2025
27 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $636 · 2022: $824 · 2023: $98.09 · 2024: $118 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $485.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $354.30 | 2021-2023 | |
| Novo Nordisk INC | $216.02 | 2021-2024 | |
| Coloplast Corp | $156.94 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $138.81 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $111.59 | 2021-2022 | |
| Pfizer INC. | $93.77 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $92.11 | 2022 | |
| Amgen INC. | $81.63 | 2022 | |
| Glaxosmithkline, LLC. | $74.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.95 | 2021-2024 | |
| Lilly USA, LLC | $66.22 | 2022-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.21 | 2021-2022 | |
| Exact Sciences Corporation | $52.74 | 2024-2025 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $45.99 | 2021 | |
| Medtronic, INC. | $36.41 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.80 | 2021 | |
| Ibsa Pharma INC. | $30.04 | 2021 | |
| Kerecis Limited | $29.44 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Organogenesis INC. | $28.52 | 2024 | |
| Currax Pharmaceuticals LLC | $27.76 | 2021-2022 | |
| Insulet Corporation | $26.34 | 2025 | Omnipod |
| Bausch Health US, LLC | $25.65 | 2022 | |
| Eisai INC. | $24.10 | 2021 | |
| Axsome Therapeutics, INC. | $23.90 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.96 | 2022 | |
| Amarin Pharma, INC. | $15.72 | 2021 | |
| Merck Sharp & Dohme LLC | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Ham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.